Skin Cancer

Vanderbilt researchers led by Ann Richmond have identified a promising drug combination that targets three key pathways in advanced melanoma, potentially restoring the immune response in patients resistant to standard immunotherapy. Although the work is preclinical, the use of drugs already in clinical trials for other conditions could accelerate testing in humans. Read More

Many melanoma patients are treated with drugs called BRAF or MEK inhibitors that specifically target the mutant proteins created in cancerous tumors.  These inhibitors can block the tumors’ ability to grow and spread. According to Ann Richmond, Ingram Professor of Cancer Research and professor of pharmacology… Read More